BlueRock’s neuronal stem cell therapy for Parkinson’s disease is first to show positive results in Phase I clinical study    - BlueRock Therapeutics LP
www.bluerocktx.com
Investigational Bemdaneprocel (BRT-DA01) was well tolerated with no major safety issues in all 12 patients through one year Assessment of secondary endpoints demonstrates feasibility of transplantation and evidence of cell survival and engraftment Phase II clinical study expected to begin enrolling patients in H1 […]

BlueRock’s neuronal stem cell therapy for Parkinson’s disease is first to show positive results in Phase I clinical study::Investigational Bemdaneprocel (BRT-DA01) was well tolerated with no major safety issues in all 12 patients through one year Assessment of secondary endpoints demonstrates feasibility of transplantation and evidence of cell survival and engraftment Phase II clinical study expected to begin enrolling patients in H1 […]